150 related articles for article (PubMed ID: 29079735)
21. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence.
Ayala G; Thompson T; Yang G; Frolov A; Li R; Scardino P; Ohori M; Wheeler T; Harper W
Clin Cancer Res; 2004 Oct; 10(19):6572-8. PubMed ID: 15475446
[TBL] [Abstract][Full Text] [Related]
22. PBX3 is a putative biomarker of aggressive prostate cancer.
Ramberg H; Grytli HH; Nygård S; Wang W; Ögren O; Zhao S; Løvf M; Katz B; Skotheim RI; Bjartell A; Eri LM; Berge V; Svindland A; Taskén KA
Int J Cancer; 2016 Oct; 139(8):1810-20. PubMed ID: 27273830
[TBL] [Abstract][Full Text] [Related]
23. Differential Patterns of Secreted Frizzled-Related Protein 4 (SFRP4) in Adipocyte Differentiation: Adipose Depot Specificity.
Guan H; Zhang Y; Gao S; Bai L; Zhao S; Cheng XW; Fan J; Liu E
Cell Physiol Biochem; 2018; 46(5):2149-2164. PubMed ID: 29730658
[TBL] [Abstract][Full Text] [Related]
24. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
25. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells.
Warrier S; Balu SK; Kumar AP; Millward M; Dharmarajan A
Oncol Res; 2013; 21(2):93-102. PubMed ID: 24406045
[TBL] [Abstract][Full Text] [Related]
26. Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression.
Chen Y; Zhang Q; Wang Q; Li J; Sipeky C; Xia J; Gao P; Hu Y; Zhang H; Yang X; Chen H; Jiang Y; Yang Y; Yao Z; Chen Y; Gao Y; Tan A; Liao M; Schleutker J; Xu J; Sun Y; Wei GH; Mo Z
Sci Rep; 2017 Jul; 7(1):4538. PubMed ID: 28674394
[TBL] [Abstract][Full Text] [Related]
27. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
28. A Role for Progesterone-Regulated sFRP4 Expression in Uterine Leiomyomas.
Delaney MA; Wan YW; Kim GE; Creighton CJ; Taylor MG; Masand R; Park A; Valdes C; Gibbons W; Liu Z; Anderson ML
J Clin Endocrinol Metab; 2017 Sep; 102(9):3316-3326. PubMed ID: 28637297
[TBL] [Abstract][Full Text] [Related]
29. Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness.
Moen LV; Ramberg H; Zhao S; Grytli HH; Sveen A; Berge V; Skotheim RI; Taskén KA; Skålhegg BS
Urol Oncol; 2017 Mar; 35(3):111.e1-111.e8. PubMed ID: 27838142
[TBL] [Abstract][Full Text] [Related]
30. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis.
Cho HY; Choi HJ; Sun HJ; Yang JY; An JH; Cho SW; Kim SW; Kim SY; Kim JE; Shin CS
Bone; 2010 Aug; 47(2):263-71. PubMed ID: 20472109
[TBL] [Abstract][Full Text] [Related]
31. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
[TBL] [Abstract][Full Text] [Related]
33. microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer.
Zedan AH; Hansen TF; Assenholt J; Pleckaitis M; Madsen JS; Osther PJS
Tumour Biol; 2018 May; 40(5):1010428318775864. PubMed ID: 29775158
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.
Dey P; Ström A; Gustafsson JÅ
Oncogene; 2014 Aug; 33(33):4213-25. PubMed ID: 24077289
[TBL] [Abstract][Full Text] [Related]
35. Elevated secreted frizzled-related protein 4 in obesity: a potential role in adipose tissue dysfunction.
Garufi G; Seyhan AA; Pasarica M
Obesity (Silver Spring); 2015 Jan; 23(1):24-7. PubMed ID: 25322919
[TBL] [Abstract][Full Text] [Related]
36. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.
Hansen AF; Sandsmark E; Rye MB; Wright AJ; Bertilsson H; Richardsen E; Viset T; Bofin AM; Angelsen A; Selnæs KM; Bathen TF; Tessem MB
Oncotarget; 2016 Jul; 7(27):42071-42085. PubMed ID: 27276682
[TBL] [Abstract][Full Text] [Related]
37. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
38. Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.
Ghoshal A; Ghosh SS
Mol Cell Biochem; 2016 Jul; 418(1-2):119-35. PubMed ID: 27334754
[TBL] [Abstract][Full Text] [Related]
39. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
40. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass.
Nakanishi R; Akiyama H; Kimura H; Otsuki B; Shimizu M; Tsuboyama T; Nakamura T
J Bone Miner Res; 2008 Feb; 23(2):271-7. PubMed ID: 17907918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
